Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$206.10 USD
-0.11 (-0.05%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $206.10 0.00 (0.00%) 7:46 PM ET
4-Sell of 5 4
C Value C Growth C Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CRL 206.10 -0.11(-0.05%)
Will CRL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CRL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRL
CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA
CRL Stock May Benefit From New Neuroscience Research Collaboration
CRL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Charles River (CRL) Down 5.3% Since Last Earnings Report?
Why Charles River (CRL) International Revenue Trends Deserve Your Attention
Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Down
Other News for CRL
BlackRock Innovation And Growth Term Trust Q2 2024 Commentary
Creightons Updates Share Capital and Voting Rights
Charles River Laboratories and CEBINA Announce Strategic Collaboration to Accelerate Cutting Edge Neuroscience Research
Charles River announces collaboration with DanubeNeuro acceleration program
BlackRock Health Sciences Term Trust Q2 2024 Commentary